



PATENT
Customer No. 22,852
Attorney Docket No. 06854.0024-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Masahiro KAJIWARA) Group Art Unit: 1625
)
Application No.: 10/669,700) Examiner: E. Huang
)
Filed: September 25, 2003)
)
For: UREASE INHIBITORS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicant brings to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement includes a certification as specified by Section 1.97(e).

Each document listed in this Information Disclosure Statement was first cited in a communication dated August 30, 2004, from the European Patent Office in a counterpart foreign application (EP 01 90 8245), and this Information Disclosure Statement is being filed within three months of the mailing date of that communication.

Copies of the listed documents are attached. Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.


Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.



By: _____
Mark J. Feldstein
Reg. No. 46,693

Dated: October 14, 2004



INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06854.0024-01	Appln. No.	10/669,700
Applicant	Masahiro KAJIWARA		
Filing Date	September 25, 2003	Group:	1625

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
EP 0 834 253 A2	Apr. 8, 1998	EUROPE			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Chemical Abstracts No. 1972:254, for Impicciatore, M. et al., "Biological properties of 1,2-benzisothiazoles. Pharmacological characteristics of 1,2-benzisoxazolin-3-one and 1,2-benzisothiazolin-3-one," Bollettino - Societa Italiana di Biologia Sperimentale, vol. 47, no. 10, pp. 296-299, 1971.
Medline Abstract No. NLM3157538, for Andersen, K.E. et al., "Biocide patch tests," Contact Dermatitis, vol. 12, no. 2, pp. 99-103, February 1985.

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce